#Combination-Therapy

2 stories

Industry June 8, 2026 · View digest

Roche Confirms Petrelintide-Enicepatide Phase 2 Combination Trial Starts Mid-2026

Genentech confirmed at its Monday investor event that the planned Phase 2 multi-arm fixed-dose combination of petrelintide (amylin analog) and enicepatide (GLP-1/GIP) starts mid-2026. The setup mirrors Novo's CagriSema and Lilly's Mounjaro-plus-amylin work, with Roche aiming for the same dual-mechanism economics that produced REIMAGINE 2's head-to-head win this week. Roche projected $9 billion in peak annual sales for the combined obesity pipeline at its Q1 print.

Clinical Trials April 15, 2026 · View digest

GLP-1 Plus SGLT2 Combination Therapy Cuts All-Cause Mortality by 29% in 220,000-Patient Study

A study of 220,043 patients published in Diabetes, Obesity and Metabolism found that combining GLP-1 receptor agonists with SGLT2 inhibitors reduced all-cause mortality by 29%, the cardiovascular composite outcome by 19%, and heart failure risk by 22% compared to SGLT2 inhibitor use alone over 1.3 years of median follow-up.